Journal of Antimicrobial Chemotherapy · 2010 · 30 citations · 28 references
PharmacyInfectious DiseasesPharmacotherapyAntimicrobial PharmacotherapyInfectious Disease PharmacotherapyMedical MicrobiologyBacterial InfectionsEmpiric Antimicrobial TherapyTreatment Of EndocarditisDaptomycin ResistanceEmpiric Therapy EvaluationInfectious EndocarditisLong-term Clinical SuccessMethicillin-resistant Staphylococcus Aureus Infection TreatmentMethicillin-resistant Staphylococcus Aureus TreatmentSkin Infection Antibiotic TherapyStaphylococcal Infection Therapy
OBJECTIVES: Recent recommendations by the Infectious Diseases Society of America for the treatment of Staphylococcus aureus suggest the use of alternative agents when vancomycin MIC values are >or=2 mg/L. This study examines the outcome of patients treated with daptomycin for S. aureus infections with documented vancomycin MICs. PATIENTS AND METHODS: All patients with skin, bacteraemia and endocarditis infections due to S. aureus with vancomycin MIC values in CORE 2005-08, a retrospective, multicentre, observational registry, were studied. The outcome (cure, improved, failure or non-evaluable) was the investigator assessment at the end of daptomycin therapy. Success was defined as cure or improved. RESULTS: Five hundred and forty-seven clinically evaluable patients were identified with discrete vancomycin MIC values [MIC <2 mg/L: 451 (82%); MIC >or=2 mg/L: 96 (18%)]. The vancomycin MIC groups were well matched for patient characteristics, types of infections, first-line daptomycin use (19%) and prior vancomycin use (58%). Clinical success was reported in 94% of patients. No differences were detected in the daptomycin success rate by the vancomycin MIC group overall or by the infection type. A multivariate logistic regression also failed to identify vancomycin MIC as a predictor of daptomycin failure. Adverse event (AE) rates were not different when analysed by MIC group; both groups had approximately 17% of patients with one AE. CONCLUSIONS: In this diverse population, daptomycin was associated with similar outcomes for patients, regardless of whether the vancomycin MIC was categorized as <2 or >or=2 mg/L. Further studies are warranted.
28
George Sakoulas, Pamela A. Moise-Broder, Jerome J. Schentag et al. · Journal of Clinical Microbiology · 2004 · 836 citations · Full text
Àlex Soriano, Francesc Marco, J. A. Martínez et al. · Clinical Infectious Diseases · 2007 · 767 citations · Full text